DB
ABCL icon

DCVC Bio’s AbCellera Biologics ABCL Stock Holding History

DCVC Bio’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,411
Closed -$313K – 1
2022
Q2 		$313K Sell
29,411
-7,276,350
-100% -$61.6M 100% 1
2022
Q1 		$71.2M Hold
7,305,761
– – 100% 1
2021
Q4 		$104M Buy
+7,305,761
New +$111M 100% 1

Other funds holding ABCL

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

DCVC Bio's ABCL Position: Q3 2022 in Review

DCVC Bio sold out of AbCellera Biologics (ABCL) in Q3 2022, closing a stake of 29,411 shares — an estimated $313K sold.

DCVC Bio first reported a position in ABCL in Q4 2021 and held it in 3 quarters. The position peaked at $104M in Q4 2021. 190 funds tracked by Wall St. Rank hold ABCL as of Q3 2022.

  • DCVC Bio reported no remaining AbCellera Biologics position as of Q3 2022 after selling out during the quarter.
  • DCVC Bio sold 29,411 AbCellera Biologics shares in Q3 2022, an estimated $313K.
  • DCVC Bio first reported a position in AbCellera Biologics in Q4 2021 and held it in 3 quarters.
  • DCVC Bio's AbCellera Biologics position peaked at $104M in Q4 2021.
  • 190 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2022.

Based on DCVC Bio's 13F filing for Q3 2022.